As a leading specialist in nonclinical ADME and Toxicology Services for over 25 years, Eurofins Discovery focuses on providing cost-effective, reproducible, high-quality data for our clients. With our fast turn-around times, flexibility, and commitment to your project, we can deliver high-quality results to meet your specific needs.
Performing early in vitro ADME screening and in vivo PK studies to better understand the Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) properties of your compounds is essential for selecting candidates with desirable profiles for later stages of drug development.
The bioavailability of a compound, the rate and extent at which the active drug enters systemic circulation, is influenced by many factors including solubility, permeability, protein binding, and metabolism. Our wide range of assays helps determine compound bioavailability, such as, aqueous solubility tests in simulated fluids, drug absorption by measuring intestinal (or MDCK) permeability rates, interactions with transporters (e.g., P-glycoprotein) that may limit exposure and protein binding assays in multiple species.
Metabolism plays a major role in both the efficacy and safety of drugs. We offer extensive Phase I and Phase II enzyme assays, including cytochrome P450 (CYP) inhibition and induction assays in all the major isoforms (3A4, 2D6, 2B6, 1A2, 2C8, 2C9, 2C19) in recombinant CYP’s, human liver microsomes and hepatocytes, and UGT phenotyping and inhibition experiments. Eurofins Discovery metabolic stability assays measure the intrinsic clearance of your compound and we offer detailed metabolic profiling for metabolite identification as well as reactive metabolite screening using state-of-the-art Mass Spectrometry instrumentation.
In the drug discovery process, understanding potential compound interactions with transporters in the early stage of development is essential for selecting candidates with desirable drug metabolism and safety profiles. To test for compound interactions with drug transporters, as recommended by regulatory agencies (P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K and more), we offer both substrate assessment and inhibition services in Caco2, MDCK, HEK293, CHO, membrane vesicles, and various transfected cells lines.
With the breadth of both in vitro ADME services from Eurofins Discovery, and in vivo PK services from our partner lab, Pharmacology Discovery Services, our clients have access to the assays and expertise, to perform studies that will enhance decision-making throughout the drug discovery process.
Our experts at Eurofins Discovery have developed a comprehensive selection of thousands of products and services for drug discovery that includes in vitro pharmacology, cell-based phenotypic assays, ADME-Tox, in vivo safety & efficacy, custom protein production and assay development. While all of our services can be ordered individually or combined, a selection of key services are provided in our drug candidate assessment packages to provide convenient access to services that enable the characterization of compounds in drug discovery research.
We provide more ADME services including:
- Compound testing for blood and plasma stability
- Glucuronide and glutathione conjugation
- Nuclear receptor activation of PXR, AhR, and CAR
- Investigating toxicities related to poor ADME PK properties
- Drug-Drug Interactions
- Lead optimization services
- In vivo PK services
